The Interaction of PI3K Inhibition with Homologous Recombination Repair in Triple Negative Breast Cancer Cells
DOI:
https://doi.org/10.18433/jpps30684Abstract
Purpose: Aberrant activation of the phosphatidylinositol 3'-kinase (PI3K)-Akt signaling pathway is observed in many types of human cancer including triple negative breast cancer (TNBC). Additionally, dysregulation in the homologous recombination (HR)-dependent DNA-repair is associated with TNBC phenotype due to BRCA1/2 mutations or HR deficiency. Therefore, the hypothesis of this study was to evaluate the association of PI3K inhibition with HR pathway in TNBC in terms of BRCA1 mutation status. Methods: To examine the potential therapeutic effect of LY294002, an inhibitor of PI3K, on TNBC cell lines with known BRCA1 status, WST-1, annexin V, cell cycle analysis and AO/EB staining were performed. Additionally, RT-PCR and immunofluorescence analysis was used to explore the interaction between the inhibition of PI3K and HR functionality. Results: The findings showed that LY294002 could significantly inhibited the proliferation of TNBC cells. Furthermore, the suppression of PI3K resulted in HR impairment by BRCA1 and RAD51 downregulation and apoptotic cell death by the induction of DNA damage and BAX overexpression. Therefore, LY294002 was more effective in BRCA1-deficient TNBC cells. Conclusions: Consequently, targeted therapies based on the interaction of PI3K inhibition with BRCA1 mutations or HR deficiency in TNBC may be a promising strategy for the treatment of patients with TNBC.
Downloads
References
Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience?. Nat. Rev. Clin. Oncol, 2010; 7(12): 683-692. doi: 10.1038/nrclinonc.2010.154.
Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clın Breast Cancer, 2009; 9(Suppl 2): 73-81. doi: 10.3816/CBC.2009.s.008.
Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol, 2016; 13(11): 674. doi: 10.1038/nrclinonc.2016.66.
Guney Eskiler G, Cecener G, Egeli U, Tunca B. Triple negative breast cancer: new therapeutic approaches and BRCA status. Apmis, 2018; 126(5): 371-379. doi: 10.1111/apm.12836.
Ratanaphan A. A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer. Int. J. Mol. Sci, 2012; 13(11): 14898-14916. doi: 10.3390/ijms131114898.
Stoppa-Lyonnet D. The biological effects and clinical implications of BRCA mutations: where do we go from here?. Eur J Hum Genet, 2016; 24(S1): S3. doi: 10.1038/ejhg.2016.93.
Hahnen E, Hauke J, Engel C, Neidhardt G, Rhiem K, Schmutzler RK. Germline mutations in triple-negative breast cancer. Breast Care, 2017; 12(1): 15-19. doi: 10.1159/000455999.
Chen CC, Feng W, Lim PX, Kass EM, Jasin M. Homology-directed repair and the role of BRCA1, BRCA2, and related proteins in genome integrity and cancer. Annu. Rev. Cancer Biol, 2018; 2: 313-336. doi: 10.1146/annurev-cancerbio-030617-050502.
Ossovskaya V, Wang Y, Budoff A, Xu Q, Lituev A, Potapova O, Vansant G, Monforte J, Daraselia N. Exploring molecular pathways of triple-negative breast cancer. Genes & cancer, 2011; 2(9): 870-879. doi: 10.1177/1947601911432496.
Belli C, Duso BA, Ferraro E, Curigliano G. Homologous recombination deficiency in triple negative breast cancer. The Breast, 2019; 45: 15-21. doi:10.1016/j.breast.2019.02.007.
Martini M, De Santis MC, Braccini L, Gulluni F, Hirsch E. PI3K/AKT signaling pathway and cancer: an updated review. Ann. Med, 2014; 46(6): 372-383. doi: 10.3109/07853890.2014.912836.
Mayer IA, Arteaga CL. The PI3K/AKT pathway as a target for cancer treatment. Ann. Med, 2016; 67: 11-28. doi: 10.1146/annurev-med-062913-051343.
Qin H, Liu L, Sun S, Zhang D, Sheng J, Li B, Yang W. The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment. PeerJ, 2018; 6: e5092. doi: 10.7717/peerj.5092.
Davis NM, Sokolosky M, Stadelman K, Abrams SL, Libra M, Candido S, Nicoletti F, Polesel J, Maestro R, D'Assoro A, Drobot L, Rakus D, Gizak A, Laidler P, Dulińska-Litewka J, Basecke J, Mijatovic S, Maksimovic-Ivanic D, Montalto G, Cervello M, Fitzgerald TL, Demidenko Z, Martelli AM, Cocco L, Steelman LS, McCubrey JA. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget, 2014; 5(13): 4603. doi: 10.18632/oncotarget.2209.
Krajewska M, Fehrmann RS, de Vries EG, van Vugt MA. Regulators of homologous recombination repair as novel targets for cancer treatment. Frontiers in genetics, 2015; 6: 96. doi: 10.3389/fgene.2015.0009.
Guimarães IS, Tessarollo NG, Lyra-Júnior PCM, dos Santos DZ, Zampier RC, de Oliveira LFRL, Siqueira KV, Silva IV, Rangel LBA. Targeting the PI3K/AKT/mTOR Pathway in Cancer Cells in Updates on Cancer Treatment (Edited by Letícia Rangel and Ian Victor Silva). 2015, doi: 10.5772/58657.
Costa RL, Han HS, Gradishar WJ. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: A review. Breast Cancer Res Treat, 2018; 169(3): 397-406. doi: 10.1007/s10549-018-4697-y.
Massihnia D, Galvano A, Fanale D, Perez A, Castiglia M, Incorvaia L, Listì A, Rizzo S, Cicero G, Bazan V, Castorina S, Russo A. Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway. Oncotarget, 2016; 7(37): 60712. doi: 10.18632/oncotarget.10858.
Zhao HF, Wang J, Shao W, Wu CP, Chen ZP, To SST, Li WP. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Mol cancer, 2017; 16(1): 100. doi: 10.1186/s12943-017-0670-3.
Zhao W, Qiu Y, Kong D. Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy. Acta Pharm Sin B, 2017; 7(1): 27-37. doi: 10.1016/j.apsb.2016.07.006.
Janku F. Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients. Cancer Treat. Rev, 2017; 59: 93-101. doi: 10.1016/j.ctrv.2017.07.005.
Raphael J, Desautels D, Pritchard KI, Petkova E, Shah PS. Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis. Eur J Cancer, 2018; 91: 38-46. doi: 10.1016/j.ejca.2017.12.010.
Akinleye A, Avvaru P, Furqan M, Song Y, Liu D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol, 2013; 6(1): 88.
Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov, 2019; 9(2): 176-198. doi: 10.1158/2159-8290.CD-18-1177.
Baselga J. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. The oncologist, 2011; 16(Supplement 1): 12-19. doi: 10.1634/theoncologist.2011-S1-12.
Cossu-Rocca P, Orrù S, Muroni MR, Sanges F, Sotgiu G, Ena S, Pira G, Murgia L, Manca A, Uras MG, Sarobba MG, Urru S, De Miglio MR. Analysis of PIK3CA mutations and activation pathways in triple negative breast cancer. PloS one, 2015; 10(11): e0141763. doi: 10.1371/journal.pone.0141763.
Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer, 2019; 18(1): 26. doi: 10.1186/s12943-019-0954-x.
Dienstmann R, Rodon J, Serra V, Tabernero J. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol. Cancer Ther , 2014; 13(5): 1021-1031. doi: 10.1158/1535-7163.MCT-13-0639.
Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, Timms JF, Waterfield MD. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J, 2007; 404(1): 15-21. doi:10.1042/BJ20061489
Liang K, Jin W, Knuefermann C, Schmidt M, Mills GB, Ang KK, Milas L, Fan Z.Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy1. Mol Cancer Ther, 2003; 2(4): 353-360.
Liu X, Shi Y, Giranda VL, Luo Y. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway sensitizes MDA-MB468 human breast cancer cells to cerulenin-induced apoptosis. Mol. Cancer Ther, 2006; 5(3): 494-501. doi: 10.1158/1535-7163.MCT-05-0049.
Imai Y, Yoshimori M, Fukuda K, Yamagishi H, Ueda Y. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation. Oncol Rep, 2012; 27(6): 1703-1709. doi: 10.3892/or.2012.1724.
Ren Y, Zhou X, Qi Y, Li G, Mei M, Yao Z. PTEN activation sensitizes breast cancer to PI3-kinase inhibitor through the β-catenin signaling pathway. Oncol Rep, 2012; 28(3): 943-948. doi: 10.3892/or.2012.1856.
Park JH, Jung KH, Kim SJ, Fang Z, Yan HH, Son MK, Kim J, Kang YW, Lee JE, Han B, Lim JH, Hong SS. Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer. Oncotarget, 2017; 8(68): 112893. doi: 10.18632/oncotarget.22850.
Philip CA, Laskov I, Beauchamp MC, Marques M, Amin O, Bitharas J, Kessous R, Kogan L, Baloch T, Gotlieb WH, Yasmeen A. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors. BMC cancer, 2017; 17(1): 638. doi: 10.1186/s12885-017-3639-0.
Wang D, Wang M, Jiang N, Zhang Y, Bian X, Wang X, Roberts TM, Zhao JJ, Liu P, Cheng H. Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer. Oncotarget, 2016; 7(11): 13153. doi: 10.18632/oncotarget.7549.
Maity A, Jiang Z, Fernandes A, Gupta AK, Kao GD. Inhibition of PI3K/Akt Signaling Impairs DNA Repair in Glioblastoma Cells Following Ionizing Radiation. Int J Radiat Oncol Biol Phys, 2007; 69(3): S591. doi: 10.1074/jbc.M703042200.
Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, Rodríguez O, Calvo MT, Aura C, Díez O, Rubio IT, Pérez J, Rodón J, Cortés J, Ellisen LW, Scaltriti M, Baselga J. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov, 2012; 2(11): 1036-1047. doi: 10.1158/2159-8290.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Journal of Pharmacy & Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
This is an open access journal with free of charge non-commercial download. At the time of submission, authors will be asked to transfer the copyright to the accepted article to the Journal of Pharmacy and Pharmaceutical Sciences. The author may purchase the copyright for $500 upon which he/she will have the exclusive copyright to the article. Nevertheless, acceptance of a manuscript for publication in the Journal is with the authors' approval of the terms and conditions of the Creative Commons copyright license Creative Common license (Attribution-ShareAlike) License for non-commercial uses.
CLOCKSS system has permission to collect, preserve, and serve this Archival Unit.
